Literature DB >> 19190951

Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS).

Boris Bigalke1, Konstantinos Stellos, Hans-Jörg Weig, Tobias Geisler, Peter Seizer, Elisabeth Kremmer, Oliver Pötz, Thomas Joos, Andreas E May, Stephan Lindemann, Meinrad Gawaz.   

Abstract

BACKGROUND: The platelet collagen receptor glycoprotein VI (GPVI) mediates platelet adhesion to subendothelial matrix and thrombus formation in acute coronary syndrome (ACS). This study examined patients with both ACS and stable coronary artery disease (CAD), which presented with atrial fibrillation (AF) and sinus rhythm (SR). METHODS AND
RESULTS: We evaluated 992 patients with acute or stable CAD, and determined platelet surface expression of GPVI using flow cytometry. Seventy-eight patients presented with nonvalvular persistent AF. After 1:1 propensity score matching 156 matched cases with 78 pairs were obtained. Patients with AF and ACS showed a significantly decreased GPVI expression compared to patients with ACS and SR, whereas patients with stable angina pectoris (SA) presented with low level activation and no significant difference between SR and AF [mean fluorescence intensity (MFI) for ACS (SR Vs. AF): 20 +/- 6.3 Vs. 17.7 +/- 4.4; P = 0.023; SA (SR Vs. AF): 18.8 +/- 9.4 Vs. 18.1 +/- 6.1; P = 0.649]. In contrast, soluble GPVI was increased in ACS and AF accordingly [plasma GPVI (ng/ml) for ACS (SR Vs. AF): 1.4 +/- 0.8 Vs. 1.9 +/- 1.1; P = 0.038; SA (SR Vs. AF): 0.9 +/- 0.4 Vs. 1.1 +/- 0.5; P = 0.127].
CONCLUSION: Platelet GPVI surface expression is decreased in patients with AF and ACS compared to patients with SR and ACS. Nonvalvular AF is related to indices of chronic platelet activation and might be responsible for a down-regulation of GPVI receptor density on platelets, while soluble GPVI was increased in ACS and AF accordingly.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190951     DOI: 10.1007/s00395-009-0779-7

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  6 in total

1.  Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban.

Authors:  Takumi Aota; Katsuki Naitoh; Hideo Wada; Yoshiki Yamashita; Noriki Miyamoto; Masahiro Hasegawa; Hiroki Wakabayashi; Kakunoshin Yoshida; Kunihiro Asanuma; Takeshi Matsumoto; Kohshi Ohishi; Yuji Shimokariya; Norikazu Yamada; Masakatsu Nishikawa; Naoyuki Katayama; Atsumasa Uchida; Akihiro Sudo
Journal:  Int J Hematol       Date:  2014-09-25       Impact factor: 2.490

Review 2.  Ischaemic stroke: a thrombo-inflammatory disease?

Authors:  Bernhard Nieswandt; Christoph Kleinschnitz; Guido Stoll
Journal:  J Physiol       Date:  2011-07-18       Impact factor: 5.182

3.  Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease.

Authors:  Boris Bigalke; Konstantinos Stellos; Tobias Geisler; Stephan Lindemann; Andreas E May; Meinrad Gawaz
Journal:  Clin Res Cardiol       Date:  2010-01-05       Impact factor: 5.460

4.  The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.

Authors:  Silvia Goebel; Zhongmin Li; Jasmin Vogelmann; Hans-Peter Holthoff; Heidrun Degen; Dirk M Hermann; Meinrad Gawaz; Martin Ungerer; Götz Münch
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

Review 5.  Targeting GPVI as a novel antithrombotic strategy.

Authors:  Robert K Andrews; Jane F Arthur; Elizabeth E Gardiner
Journal:  J Blood Med       Date:  2014-05-21

6.  Platelet Carcinoembryonic Antigen Cell Adhesion Molecule 5 (CEACAM5) as a Possible Novel Diagnostic Tool for Evaluation of Acute Coronary Syndrome.

Authors:  Wen Wan; Yujia Ye; Huawei Wang; Longjun Li; Yajuan Gu; Lai Yang; Lihong Yang; Han Liu; Chao Meng; Deng Li; Zhe Wang; Zhaohui Meng
Journal:  Med Sci Monit       Date:  2019-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.